-
公开(公告)号:US20210401892A1
公开(公告)日:2021-12-30
申请号:US17472293
申请日:2021-09-10
Applicant: Immatics Biotechnologies GmbH
Inventor: Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , A61K45/06 , A61K39/12 , A61K39/395 , A61K38/08 , A61K39/00 , C07K14/47 , A61P35/02 , C07K7/06 , C07K14/54 , C07K16/24 , C12N5/0783
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
52.
公开(公告)号:US20210395336A1
公开(公告)日:2021-12-23
申请号:US17396345
申请日:2021-08-06
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , A01N37/46 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
53.
公开(公告)号:US20210353728A1
公开(公告)日:2021-11-18
申请号:US17333977
申请日:2021-05-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
54.
公开(公告)号:US20210346481A1
公开(公告)日:2021-11-11
申请号:US17327487
申请日:2021-05-21
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210338734A1
公开(公告)日:2021-11-04
申请号:US17377724
申请日:2021-07-16
Applicant: Immatics Biotechnologies GmbH
Inventor: Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
56.
公开(公告)号:US20210290745A1
公开(公告)日:2021-09-23
申请号:US17339303
申请日:2021-06-04
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
57.
公开(公告)号:US20210290744A1
公开(公告)日:2021-09-23
申请号:US17333929
申请日:2021-05-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210283230A1
公开(公告)日:2021-09-16
申请号:US17320938
申请日:2021-05-14
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC: A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210277086A1
公开(公告)日:2021-09-09
申请号:US17314650
申请日:2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210277080A1
公开(公告)日:2021-09-09
申请号:US17314397
申请日:2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules
-
-
-
-
-
-
-
-
-